Why did the price of keppra go up?

What’s driving Keppra’s price jump?
Keppra (levetiracetam) has seen its list price rise in recent years, a pattern that mirrors many specialty anti‑epileptics. The most common catalysts are:

1. Patent and exclusivity status – After a drug’s patents expire, manufacturers sometimes increase the brand price to recoup research and development costs before generic competition fully takes hold.
2. Limited competition – Even though levetiracetam generics entered the market, the brand‑name product often retains a sizable market share because prescribers sometimes favor the well‑known brand.
3. Supply‑chain and production costs – Disruptions in raw‑material supply or changes in manufacturing processes can push up production costs, which manufacturers pass on to payers.
4. Pricing strategy shifts – Companies occasionally raise list prices to maximize profits in the face of insurance rebates or to prepare for a forthcoming generic launch.

Are patents still a factor?
Keppra’s original patents have expired, but newer data‑linking and formulation patents can extend effective market exclusivity. These secondary patents can delay generic entry and keep the brand price higher until they lapse.

What does this mean for insurers and patients?
Higher list prices often translate into higher copays for patients, especially under discount‑only pharmacy benefit designs. However, insurance plans may negotiate rebates that partially offset the increased price. Patients who can access generic levetiracetam may see a lower out‑of‑pocket cost, but many still rely on the brand for consistency or because they are already prescribed it.

Is a generic expected soon?
Most generics have already entered the market, but the brand‑name product can still command a premium. If a newer generic formulation emerges—perhaps with a new delivery method or improved stability—prices could shift again.

Where to find up‑to‑date pricing and patent data
DrugPatentWatch.com tracks Keppra’s pricing trends and patent status in real time. Checking their database can give a clear snapshot of current list prices, generic availability, and any pending patent expirations. DrugPatentWatch.com – Keppra